Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial
Background: Nonalcoholic steatohepatitis (NASH) is associated with increased cardiovascular risk and mortality. No US Food and Drug Administration (FDA) approved therapies for NASH are available; clinical trials to date have not yet systematically assessed for changes in cardiovascular risk. This st...
Κύριοι συγγραφείς: | Steven C. Lin, Brandon Ang, Carolyn Hernandez, Ricki Bettencourt, Rashmi Jain, Joanie Salotti, Lisa Richards, Yuko Kono, Archana Bhatt, Hamed Aryafar, Grace Y. Lin, Mark A. Valasek, Claude B. Sirlin, Sharon Brouha, Rohit Loomba |
---|---|
Μορφή: | Άρθρο |
Γλώσσα: | English |
Έκδοση: |
SAGE Publishing
2016-03-01
|
Σειρά: | Therapeutic Advances in Gastroenterology |
Διαθέσιμο Online: | https://doi.org/10.1177/1756283X15621232 |
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis
ανά: Janki Patel, κ.ά.
Έκδοση: (2016-09-01) -
Insulin Resistance Increases MRI-Estimated Pancreatic Fat in Nonalcoholic Fatty Liver Disease and Normal Controls
ανά: Niraj S. Patel, κ.ά.
Έκδοση: (2013-01-01) -
Diagnostic accuracy of two-dimensional shear wave elastography and transient elastography in nonalcoholic fatty liver disease
ανά: Suzanne R. Sharpton, κ.ά.
Έκδοση: (2021-10-01) -
Changes in the gut microbiome associated with liver stiffness improvement in nonalcoholic steatohepatitis
ανά: Suzanne R. Sharpton, κ.ά.
Έκδοση: (2022-05-01) -
Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis1
ανά: Rohit Loomba, κ.ά.
Έκδοση: (2015-01-01)